Compare IXHL & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | ZTEK |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 68.8M |
| IPO Year | 2024 | 2022 |
| Metric | IXHL | ZTEK |
|---|---|---|
| Price | $3.98 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 384.0K | 149.1K |
| Earning Date | 05-15-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.40 |
| 52 Week High | $6.39 | $1.65 |
| Indicator | IXHL | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 51.97 |
| Support Level | $0.34 | $0.49 |
| Resistance Level | $5.08 | $0.82 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 24.88 | 39.59 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.